January 31, 2012 -- To promote the research and registration of innovative therapeutics in Beijing, the Beijing FDA has issued a new set of guidelines for fast-track review, effective February 12, 2012. The new set of rules mandate a review time of just 15 working days, down from 30 working days under the previous guidelines. Also, seven categories of drugs now qualify for fast-track status in Beijing, against four categories of eligible candidates in the national-level SFDA. More details...
